Fixed dosing of alpelisib for children with vascular anomalies: Can we do better?
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16388 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Amandine Remy und 9 weiteren Autor:innen. Beteiligte Einrichtung: General Pediatric Fellowship Program, Sainte-Justine University Hospital, Université de Montréal, Montreal, Canada. Hauptthemen laut MEDLINE: Vascular Malformations, Thiazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Unité de recherche en pharmacologie, Research Center CHU Sainte-Justine, Mitacs Globalink.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Severe forms of vascular malformations (VM) can highly impact patients' quality of life and lead to life‐threatening organ dysfunction. Numerous VM are caused by somatic activating mutations in the PI3K/AKT/mTOR signalling pathway. Alpelisib, a PIK3CA inhibitor was recently FDA‐approved for paediatric PIK3CA‐related overgrowth syndrome (PROS). However, an empiric and fixed dose of 50 mg was selected, irrespective of weight, in the absence of any pharmacokinetic (PK) data. We aim to report novel alpelisib PK data in children to support dosing decisions. Nine patients with severe VM (PROS: n = 4, other VM: n = 5) were included. Mean age was 10.5 years (SD = 5.2 years), and mean weight was 43 kg (SD = 24 kg). AUC on the fixed dose of 50 mg/day was highly variable (mean = 7035 ng*h/mL, SD = 4057, CV = 58%). AUC was correlated with weight. As short‐ and long‐term adverse effects to alpelisib in children are unknown, a dosing based on PK data is urgently needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Pediatric Fellowship Program, Sainte-Justine University Hospital, Université de Montréal, Montreal, Canada.
- Pharmacology Master of Science Program, Department of Physiology and Pharmacology, Université de Montréal, Montreal, Canada.
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
- Département Clinique de Médecine de Laboratoire, Secteur Pharmacologie Clinique, Optilab Montréal, Sainte-Justine University Hospital, Montreal, Canada.
- Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- Vascular Anomaly Team, Sainte-Justine University Hospital, Université de Montréal, Canada.
ORCID-Profile: Amandine Remy, Facundo Garcia-Bournissen
Förderung
- Unité de recherche en pharmacologie
- Research Center CHU Sainte-Justine
- Mitacs Globalink
Zitieren
APA
Remy, A., Etingin, A., Gavra, P., Garcia-Bournissen, F., Essouri, S., Denoncourt, A., Tran, T. H., Dubois, J., Théorêt, Y., & Kleiber, N. (2025). Fixed dosing of alpelisib for children with vascular anomalies: Can we do better?. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16388
Vancouver
Remy A, Etingin A, Gavra P, Garcia-Bournissen F, Essouri S, Denoncourt A, et al. Fixed dosing of alpelisib for children with vascular anomalies: Can we do better?. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16388
BibTeX
@article{Remy2025,
author = {Remy, Amandine and Etingin, Albert and Gavra, Paul and Garcia-Bournissen, Facundo and Essouri, Sandrine and Denoncourt, Audrey and Tran, Thai Hoa and Dubois, Josée and Théorêt, Yves and Kleiber, Niina},
title = {Fixed dosing of alpelisib for children with vascular anomalies: Can we do better?},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16388}
}
EUVIMED